BioLineRx Ltd.
BLRXHealthcare|Biotechnology|IL
$1.71
-0.06 (-3.28%)
DCF Value
$0.18
Tangible Book / Share
$0.00
Cash / Share
$0.07
Financials
Financial Snapshot
Market Cap
$8.5M
Enterprise Value
$12.8M
Revenue (TTM)
$1.4M
Net Income (TTM)
-$8.0M
Cash & Investments
$13.1M
Net Cash
$5.1M
Free Cash Flow (TTM)
-$10.9M
Operating CF (TTM)
-$10.9M
Debt/Equity
0.58
Cash Runway & Burn Rate
Cash on Hand
$13.1M
Quarterly Burn
$2.7M
Monthly Burn
$906.4K
Est. Runway
~4.8 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $35.6M | $49.5M | $30.2M | $27.5M | $22.6M | $57.1M | $51.1M | $43.0M | $19.6M | $20.9M | $13.1M | |
| Operating Cash Flow | -$14.5M | -$20.5M | -$24.2M | -$22.7M | -$23.2M | -$23.6M | -$26.2M | -$22.6M | -$43.9M | -$8.1M | -$10.9M | |
| Free Cash Flow | -$14.6M | -$24.8M | -$34.4M | -$22.7M | -$23.2M | -$23.7M | -$26.6M | -$22.9M | -$43.9M | -$8.2M | -$10.9M | |
| Capital Expenditure | -$55.0K | -$4.2M | -$10.2M | -$73.0K | $0.00 | -$97.0K | -$316.0K | -$297.0K | -$54.0K | -$25.2K | -$25.2K | |
| Financing Cash Flow | $2.1M | $38.7M | $13.1M | $19.2M | $17.9M | $57.7M | $20.4M | $15.1M | $20.7M | $9.0M | -$4.5M |
R&D Spending
R&D (TTM)
$9.7M
R&D Intensity
692.3%
R&D Growth vs Prior
+26.4%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.8M | $28.9M | $1.2M | $1.4M | |
| R&D Expense | $11.2M | $19.5M | $19.8M | $23.4M | $18.2M | $19.5M | $17.6M | $12.5M | $9.1M | $7.7M | $9.7M | |
| R&D % of Revenue | — | — | — | — | — | — | — | 260.8% | 31.6% | 643.9% | 692.3% | |
| SG&A | $5.3M | $5.7M | $5.8M | $4.6M | $4.7M | $5.3M | $11.5M | $31.2M | $28.5M | $3.1M | $3.5M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.8M | $28.9M | $1.2M | $1.4M | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.7M | $9.3M | $759.0K | $422.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.1M | $19.7M | $430.4K | $976.3K | |
| R&D | $11.2M | $19.5M | $19.8M | $23.4M | $18.2M | $19.5M | $17.6M | $12.5M | $9.1M | $7.7M | $9.7M | |
| SG&A | $5.3M | $5.7M | $5.8M | $4.6M | $4.7M | $5.3M | $11.5M | $31.2M | $28.5M | $3.1M | $3.5M | |
| Operating Income | -$16.5M | -$25.2M | -$25.6M | -$28.1M | -$22.9M | -$24.8M | -$29.2M | -$49.7M | -$20.4M | -$10.4M | -$12.3M | |
| Interest Expense | $14.0K | $21.0K | $21.0K | $1.8M | $1.5M | $984.0K | $2.2M | $2.2M | $9.2M | $1.3M | $1.0M | |
| Pretax Income | -$15.8M | -$24.4M | -$23.0M | -$25.4M | -$30.0M | -$27.1M | -$25.0M | -$60.6M | -$9.2M | -$2.0M | -$10.2M | |
| Net Income | -$15.8M | -$24.4M | -$23.0M | -$25.4M | -$30.0M | -$27.1M | -$25.0M | -$60.6M | -$9.2M | -$1.2M | -$8.0M | |
| EPS (Diluted) | -168.00 | -162.00 | -126.00 | -108.00 | -72.00 | -24.48 | -19.32 | -37.74 | -4.62 | -0.29 | -1.82 | |
| EBITDA | -$16.0M | -$24.8M | -$21.9M | -$22.7M | -$27.6M | -$25.4M | -$22.1M | -$57.1M | $3.9M | -$224.8K | -$8.3M | |
| Shares Out. (M) | 0.09 | 0.15 | 0.18 | 0.24 | 0.42 | 1.10 | 1.29 | 1.61 | 2.00 | 4.11 | 4.44 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.5M | $5.1M | $3.4M | $5.3M | $16.8M | $13.0M | $10.6M | $4.3M | $10.4M | $3.2M | $4.6M | |
| Short-Term Investments | $33.2M | $44.4M | $26.7M | $22.2M | $5.8M | $44.1M | $40.5M | $38.7M | $9.1M | $17.6M | $8.5M | |
| Total Current Assets | $36.1M | $50.4M | $32.0M | $28.2M | $22.9M | $57.4M | $52.0M | $47.2M | $27.1M | $23.7M | $16.3M | |
| Total Assets | $38.9M | $61.0M | $56.2M | $53.6M | $47.3M | $81.4M | $76.4M | $63.9M | $38.9M | $40.9M | $33.5M | |
| Total Current Liabilities | $3.7M | $6.7M | $6.8M | $12.0M | $10.6M | $9.7M | $10.7M | $42.8M | $15.4M | $12.1M | $13.7M | |
| Long-Term Debt | $250.0K | $157.0K | $7.8M | $5.8M | $2.7M | $0.00 | $8.6M | $6.6M | $9.0M | $4.5M | $2.2M | |
| Total Liabilities | $3.9M | $8.1M | $14.9M | $20.2M | $25.3M | $13.3M | $25.5M | $50.7M | $25.4M | $17.6M | $16.9M | |
| Stockholders' Equity | $35.0M | $52.9M | $41.3M | $33.4M | $22.0M | $68.1M | $50.8M | $13.2M | $13.5M | $18.2M | $13.8M | |
| Retained Earnings | -$175.2M | -$199.6M | -$222.5M | -$248.0M | -$278.0M | -$305.0M | -$330.0M | -$390.6M | -$399.8M | -$401.0M | -$405.6M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.5M | -$20.5M | -$24.2M | -$22.7M | -$23.2M | -$23.6M | -$26.2M | -$22.6M | -$43.9M | -$8.1M | -$10.9M | |
| Capital Expenditure | -$55.0K | -$4.2M | -$10.2M | -$73.0K | $0.00 | -$97.0K | -$316.0K | -$297.0K | -$54.0K | -$25.2K | -$25.2K | |
| Free Cash Flow | -$14.6M | -$24.8M | -$34.4M | -$22.7M | -$23.2M | -$23.7M | -$26.6M | -$22.9M | -$43.9M | -$8.2M | -$10.9M | |
| Investing Cash Flow | $9.3M | -$15.9M | $9.6M | $5.3M | $16.7M | -$38.2M | $4.0M | $1.4M | $29.4M | -$8.6M | $12.4M | |
| Financing Cash Flow | $2.1M | $38.7M | $13.1M | $19.2M | $17.9M | $57.7M | $20.4M | $15.1M | $20.7M | $9.0M | -$4.5M | |
| Issuance of Stock | $2.2M | $38.8M | $3.8M | $20.3M | $19.2M | $50.4M | $14.4M | $14.1M | $16.4M | $14.0M | $394.7K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$93.0K | -$93.0K | $9.2M | -$1.1M | -$3.4M | -$3.6M | $6.1M | -$2.0M | $4.3M | -$4.5M | -$4.7M | |
| Stock Based Comp. | $1.1M | $1.5M | $2.5M | $1.8M | $1.3M | $1.5M | $2.2M | $2.3M | $1.1M | $0.00 | $179.0K | |
| Net Change in Cash | -$3.1M | $2.6M | -$1.7M | $1.9M | $11.5M | -$3.8M | -$2.4M | -$6.3M | $6.2M | -$7.2M | -$2.6M |
Dilution Tracker
Shares outstanding grew 875.0% over 5 years — significant dilution
Shares Outstanding
5M
5-Year Share Growth
+875.0%
Stock Issuance (TTM)
$394.7K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.09 | 0.15 | 0.18 | 0.24 | 0.42 | 1.10 | 1.29 | 1.61 | 2.00 | 4.11 | 4.44 | |
| Change vs Prior % | — | 60.2% | 20.7% | 34.8% | 72.7% | 162.2% | 16.8% | 24.5% | 24.4% | 105.8% | 8.1% | |
| Stock Issuance | $2.2M | $38.8M | $3.8M | $20.3M | $19.2M | $50.4M | $14.4M | $14.1M | $16.4M | $14.0M | $394.7K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.1M | $1.5M | $2.5M | $1.8M | $1.3M | $1.5M | $2.2M | $2.3M | $1.1M | $0.00 | $179.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | — | — | 23.1% | 68.0% | 36.2% | 69.8% | |
| Operating Margin % | — | — | — | — | — | — | — | -1035.3% | -70.5% | -871.8% | -876.3% | |
| Net Margin % | — | — | — | — | — | — | — | -1262.8% | -31.9% | -99.6% | -574.3% | |
| EBITDA Margin % | — | — | — | — | — | — | — | -1189.3% | 13.5% | -18.9% | -591.0% | |
| FCF Margin % | — | — | — | — | — | — | — | -477.2% | -151.8% | -686.4% | -779.7% | |
| ROE % | -45.2% | -46.1% | -55.6% | -76.2% | -136.3% | -39.7% | -49.1% | -458.4% | -68.5% | -6.5% | -47.2% | |
| ROA % | -40.7% | -39.9% | -40.8% | -47.5% | -63.5% | -33.2% | -32.7% | -94.8% | -23.7% | -2.9% | -24.2% | |
| ROIC % | -46.7% | -46.5% | -50.8% | -63.2% | -57.4% | -33.2% | -43.1% | -200.3% | -71.6% | -31.0% | -50.1% | |
| R&D / Revenue % | — | — | — | — | — | — | — | 260.8% | 31.6% | 643.9% | 692.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 502.9% | -95.9% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1675.9% | -97.8% | |
| Operating Income | -2.0% | -52.8% | -1.4% | -9.8% | 18.4% | -8.1% | -17.7% | -70.4% | 58.9% | 49.2% | |
| Net Income | -10.0% | -53.7% | 5.7% | -10.8% | -18.0% | 9.9% | 7.8% | -142.9% | 84.8% | 87.2% | |
| EPS (Diluted) | 0.0% | 3.6% | 22.2% | 14.3% | 33.3% | 66.0% | 21.1% | -95.3% | 87.8% | 93.7% | |
| Operating Cash Flow | -2.4% | -41.6% | -17.7% | 6.3% | -2.4% | -1.6% | -11.3% | 13.8% | -94.1% | 81.5% | |
| Free Cash Flow | 13.7% | -70.1% | -38.8% | 33.9% | -2.1% | -2.0% | -12.2% | 13.7% | -91.8% | 81.4% | |
| R&D Expense | -2.7% | 74.6% | 1.5% | 18.3% | -22.5% | 7.1% | -9.4% | -29.0% | -26.9% | -16.3% | |
| SG&A Expense | 14.1% | 8.0% | 0.7% | -20.4% | 1.9% | 12.5% | 118.8% | 170.9% | -8.6% | -89.0% | |
| Total Assets | -24.1% | 56.6% | -7.8% | -4.7% | -11.7% | 72.1% | -6.2% | -16.3% | -39.1% | 5.1% | |
| Book Value / Share | -32.7% | -5.8% | -35.3% | -40.1% | -61.8% | 17.9% | -36.0% | -79.1% | -18.1% | -15.7% | |
| Debt | -21.5% | -27.1% | 3393.2% | 19.7% | -26.5% | -39.5% | 165.0% | -5.9% | 29.8% | -32.5% | |
| Diluted Shares | 9.3% | 60.2% | 20.7% | 34.8% | 72.7% | 162.2% | 16.8% | 24.5% | 24.4% | 105.8% |
Valuation
P/E (TTM)At Loss
P/S6.75
10Y Low / Med / High0.59 / 9.57 / 21.01
P/B0.61
10Y Low / Med / High0.60 / 1.32 / 7.63
EV/EBITDAAt Loss
EV/Revenue9.15
10Y Low / Med / High0.75 / 15.37 / 22.53
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.18
Tangible Book / Share
$0.00
Cash / Share
$0.07
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -3.29 | -4.04 | -2.08 | -0.83 | -1.40 | -3.33 | -1.22 | -1.66 | -1.85 | -9.57 | -1.02 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.01 | 0.59 | 9.57 | 6.75 | |
| P/B Ratio | 1.48 | 1.85 | 1.15 | 0.66 | 1.93 | 1.32 | 0.60 | 7.63 | 1.27 | 0.63 | 0.61 | |
| EV/EBITDA | -3.09 | -3.76 | -2.41 | -1.20 | -1.21 | -3.23 | -1.45 | -1.89 | 5.54 | -81.33 | -1.13 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.53 | 0.75 | 15.37 | 9.15 |
Analyst Estimates & Quality
Altman Z-Score
-17.37
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $1.6M | $2.2M | $7.8M |
| Net Income | -$6.5M | -$5.2M | -$1.3M |
| EPS | $-1.57 | $-1.26 | $-0.33 |
| # Analysts (EPS) | 1 | 1 | 1 |